Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Soligenix Inc SNGX

Healthcare Biotechnology
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics segment is developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe... see more

Bullboard (NDAQ:SNGX)

View:
Prev 1 2
Post by Iseneschalon Nov 30, 2023 11:36am

SNGX.....Halted on the way down

Gotta back fill those gaps ; )
29
Post by Iseneschalon Nov 30, 2023 9:17am

SNGX....early a.m runner up on NR

Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Beh ƒ §et's Disease 2023-11-30 04:30 ET - News Release Pipeline ...more  
52
Post by Shanemorg58on Jan 12, 2023 10:54am

Strong Hold!

Soligenix On Track to Deliver Important Front-Line Treatment to US Market in 2024!! Super excited for whats coming. https://finance.yahoo.com/news/soligenix-track-deliver-important-front-133000799 ...more  
70
Post by Shanemorg58on Nov 17, 2022 11:57am

upcoming webinar!

https://us06web.zoom.us/webinar/register/WN_bIGC3Z_OT5q8RVoQvlMfwg Sign up for the upcoming webinar that will cover late stage pipeline work and Q4 2022 milestones!  
54
Post by HariboSpeedPeakon Jul 21, 2022 4:59pm

Benzinga Article on Soligenix

Definitely worth the read if youre thinking about investing in Soligenix or already have. Some great stuff in this article https://www.benzinga.com/general/biotech/22/07/28139372/soligenix-shares ...more  
127
Post by HariboSpeedPeakon Jul 20, 2022 2:28pm

Soligenix HyBryte Phase 3 Flash Study, Significant Results

Soligenix’s successful Phase 3 FLASH study evaluating HyBryteTM for the treatment of cutaneous T-cell lymphoma has been published in the Journal of the American Medical Association Dermatology. The ...more  
74
Post by Shanemorg58on May 20, 2022 12:13pm

Huge potential in 2022

https://finance.yahoo.com/news/sngx-phase-2a-trial-sgx302-143000280.html Phase 2a trial of SGX302 in psoriasis coming in the second half of 2022! Feeling bullish on this!
80
Post by Shanemorg58on May 19, 2022 11:24am

Strong Hold!

Love seeing more insiders buying! They must be confident on whats to come. https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=116715658&type=HTML&symbol=SNGX& ...more  
110
Post by borrockon Nov 25, 2020 2:30pm

Future trend

ZACKS SCR IS BULLISH ON SOLIGENIX, SUGGESTING 580% UPSIDE; MULTIPLE ASSETS COMBINE TO SET UP THREE NEAR-TERM POTENTIAL CATALYSTS  ...more  
800
Prev 1 2
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities